A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

Robert Pascuzzi, Jeremy Shefner, Amy S. Chappell, John S. Bjerke, Roy Tamura, Vinay Chaudhry, Lora Clawson, Lisa Haas, Jeffrey D. Rothstein

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15% less in talampanel treated subjects, and decline in ALSFRS was 30% slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8% talampanel, 5% placebo) and drug discontinuation rates (25% talampanel, 16% placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.

Original languageEnglish
Pages (from-to)266-271
Number of pages6
JournalAmyotrophic Lateral Sclerosis
Volume11
Issue number3
DOIs
StatePublished - 2010

Fingerprint

GYKI 53405
Amyotrophic Lateral Sclerosis
Placebos
Muscle Strength
Arm
Outcome Assessment (Health Care)
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid

Keywords

  • Clinical trials
  • Excitotoxicity
  • Glutamate
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Pascuzzi, R., Shefner, J., Chappell, A. S., Bjerke, J. S., Tamura, R., Chaudhry, V., ... Rothstein, J. D. (2010). A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 11(3), 266-271. https://doi.org/10.3109/17482960903307805

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. / Pascuzzi, Robert; Shefner, Jeremy; Chappell, Amy S.; Bjerke, John S.; Tamura, Roy; Chaudhry, Vinay; Clawson, Lora; Haas, Lisa; Rothstein, Jeffrey D.

In: Amyotrophic Lateral Sclerosis, Vol. 11, No. 3, 2010, p. 266-271.

Research output: Contribution to journalArticle

Pascuzzi, R, Shefner, J, Chappell, AS, Bjerke, JS, Tamura, R, Chaudhry, V, Clawson, L, Haas, L & Rothstein, JD 2010, 'A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis', Amyotrophic Lateral Sclerosis, vol. 11, no. 3, pp. 266-271. https://doi.org/10.3109/17482960903307805
Pascuzzi, Robert ; Shefner, Jeremy ; Chappell, Amy S. ; Bjerke, John S. ; Tamura, Roy ; Chaudhry, Vinay ; Clawson, Lora ; Haas, Lisa ; Rothstein, Jeffrey D. / A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. 2010 ; Vol. 11, No. 3. pp. 266-271.
@article{5efd49d5a3d14806a5c9fa1023a3a8dd,
title = "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis",
abstract = "Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15{\%} less in talampanel treated subjects, and decline in ALSFRS was 30{\%} slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8{\%} talampanel, 5{\%} placebo) and drug discontinuation rates (25{\%} talampanel, 16{\%} placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.",
keywords = "Clinical trials, Excitotoxicity, Glutamate, Therapy",
author = "Robert Pascuzzi and Jeremy Shefner and Chappell, {Amy S.} and Bjerke, {John S.} and Roy Tamura and Vinay Chaudhry and Lora Clawson and Lisa Haas and Rothstein, {Jeffrey D.}",
year = "2010",
doi = "10.3109/17482960903307805",
language = "English",
volume = "11",
pages = "266--271",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

AU - Pascuzzi, Robert

AU - Shefner, Jeremy

AU - Chappell, Amy S.

AU - Bjerke, John S.

AU - Tamura, Roy

AU - Chaudhry, Vinay

AU - Clawson, Lora

AU - Haas, Lisa

AU - Rothstein, Jeffrey D.

PY - 2010

Y1 - 2010

N2 - Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15% less in talampanel treated subjects, and decline in ALSFRS was 30% slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8% talampanel, 5% placebo) and drug discontinuation rates (25% talampanel, 16% placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.

AB - Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15% less in talampanel treated subjects, and decline in ALSFRS was 30% slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8% talampanel, 5% placebo) and drug discontinuation rates (25% talampanel, 16% placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.

KW - Clinical trials

KW - Excitotoxicity

KW - Glutamate

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77952168830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952168830&partnerID=8YFLogxK

U2 - 10.3109/17482960903307805

DO - 10.3109/17482960903307805

M3 - Article

C2 - 19961264

AN - SCOPUS:77952168830

VL - 11

SP - 266

EP - 271

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 3

ER -